**Question:** Efalizumab is used in treatment of:

A. Multiple Sclerosis
B. Psoriasis
C. Asthma
D. Chronic Obstructive Pulmonary Disease (COPD)

**Core Concept:**
Efalizumab is a human monoclonal antibody that targets and inhibits the interaction between CD11a (leukocyte function-associated antigen 1) and CD58 (T cell activation ligand), thereby modulating T cell activation and reducing inflammation. This drug is primarily used to treat immune-mediated inflammatory conditions affecting the skin and/or mucous membranes.

**Why the Correct Answer is Right:**
Efalizumab is primarily used to treat psoriasis, a chronic immune-mediated inflammatory skin disorder characterized by excessive proliferation of keratinocytes and infiltration of immune cells. By inhibiting T cell activation, efalizumab helps in suppressing the inflammation and alleviating symptoms.

**Why Each Wrong Option is Incorrect:**
A. Multiple Sclerosis (MS) is a demyelinating disease affecting the central nervous system, not skin or mucous membranes. Efalizumab is not indicated for MS treatment.
B. Psoriasis is the correct indication for efalizumab, as mentioned above. However, it is not approved for treating asthma, which is a respiratory disorder.
C. Asthma is a respiratory condition involving airway inflammation and narrowing, not skin or mucous membranes. Efalizumab is not indicated for asthma treatment.
D. Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disorder caused by long-term exposure to noxious particles or gases, not immune-mediated inflammatory skin conditions. Efalizumab is not approved for treating COPD.

**Clinical Pearl:**
Efalizumab is an example of a biological therapy targeting specific immune pathways to treat immune-mediated inflammatory disorders. It highlights the importance of considering the disease indication when choosing appropriate treatment options for patients.